<DOC>
	<DOCNO>NCT02457611</DOCNO>
	<brief_summary>The primary objective study determine antiviral efficacy , safety , tolerability ledipasvir/sofosbuvir ( LDV/SOF ) fixed-dose combination ( FDC ) adult acute genotype 1 4 hepatitis C virus ( HCV ) chronic human immunodeficiency virus ( HIV ) -1 co-infection .</brief_summary>
	<brief_title>Safety Efficacy Ledipasvir/Sofosbuvir ( LDV/SOF ) Fixed-Dose Combination ( FDC ) 6 Weeks Adults With Acute Genotype 1 4 Hepatitis C Virus ( HCV ) Chronic Human Immunodeficiency Virus ( HIV ) -1 Co-Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Coinfection</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<mesh_term>Ledipasvir</mesh_term>
	<mesh_term>Ledipasvir , sofosbuvir drug combination</mesh_term>
	<criteria>Key Acute , untreated , hepatitis C infection , genotype 1 4 , estimate duration less 24 week Confirmed HIV1 infection CD4 T cell count &gt; 200/μL individual receive antiretroviral therapy ( ART ) , CD4 T cell count &gt; 500/μL screening individual without ART Use two effective contraception method female childbearing potential sexually active male female partner Key Pregnant nurse female male pregnant female partner Chronic liver disease non HCV etiology Coinfection hepatitis B virus ( HBV ) Treatment investigational drug device within 60 day screen visit . History clinically significant illness medical disorder may interfere individual 's treatment , assessment compliance protocol Note : Other protocol define Inclusion/Exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>